On January 19, 2023, the FDA Commissioner, Robert M. Califf, delivered remarks at the FDA-USPTO Public Workshop. He noted that, since the issuance of President Biden’s 2021 Executive Order on Promoting Competition, the FDA...more
As 2021 comes to a close, Big Molecule Watch reviews the top five biosimilar regulatory developments of the year...
President Biden Signs Orange Book Transparency Act -
In January, we reported that President Biden...more
12/31/2021
/ Biden Administration ,
Biosimilars ,
BPCIA ,
Drug Pricing ,
Executive Orders ,
Federal Trade Commission (FTC) ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Guidance Update ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Orange Book ,
Patent Applications ,
Patent Examinations ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Post-Grant Review ,
Prescription Drugs ,
Purple Book ,
Statutory Requirements ,
Transparency ,
USPTO